pdf   xlsx method abbreviations

squamous cell - mNSCLC - L1, anti-PD-(L)1 versus paclitaxel plus carboplatin, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.88 [0.73, 1.06]< 10%1 study (1/-)91.6 %NAnot evaluable crucial-
progression or deaths (PFS) 0.71 [0.60, 0.85]< 10%1 study (1/-)100.0 %NAnot evaluable important-
DOR 2.14 [1.13, 4.04]< 10%1 study (1/-)1.0 %NAnot evaluable non important-
objective responses (ORR) 1.42 [1.05, 1.92]> 10%1 study (1/-)98.9 %NAnot evaluable non important-

safety endpoints 00

AE (any grade) 5.12 [1.11, 23.56]< 10%1 study (1/-)1.8 %NAnot evaluable non important-
AE (grade 3-4) 1.37 [0.98, 1.90]< 10%1 study (1/-)3.3 %NAnot evaluable non important-
AE leading to death (grade 5) 2.59 [1.36, 4.92]< 10%1 study (1/-)0.2 %NAnot evaluable non important-
AE leading to treatment discontinuation (any grade) 2.09 [1.45, 3.02]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
SAE (any grade) 2.28 [1.66, 3.14]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
STRAE (any grade) 2.27 [1.46, 3.51]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
TRAE (any grade) 1.80 [0.98, 3.28]< 10%1 study (1/-)2.8 %NAnot evaluable non important-
TRAE (grade 3-4) 1.57 [1.14, 2.15]< 10%1 study (1/-)0.3 %NAnot evaluable non important-
TRAE leading to death (grade 5) 1.34 [0.30, 6.02]< 10%1 study (1/-)35.3 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Adrenal insufficiency TRAE (grade 3-4) 2.00 [0.07, 59.91]< 10%1 study (1/-)34.7 %NAnot evaluable non important-
Alopecia TRAE (grade 3-4) 1.00 [0.02, 50.55]< 10%1 study (1/-)50.0 %NAnot evaluable non important-
Anaemia TRAE (grade 3-4) 1.09 [0.76, 1.58]< 10%1 study (1/-)31.9 %NAnot evaluable non important-
Arthralgia TRAE (grade 3-4) 1.00 [0.02, 50.55]< 10%1 study (1/-)50.0 %NAnot evaluable non important-
Asthenia TRAE (grade 3-4) 0.77 [0.28, 2.10]< 10%1 study (1/-)69.3 %NAnot evaluable non important-
Colitis TRAE (grade 3-4) 8.08 [0.43, 153.53]< 10%1 study (1/-)8.4 %NAnot evaluable non important-
Constipation TRAE (grade 3-4) 0.50 [0.02, 14.93]< 10%1 study (1/-)65.3 %NAnot evaluable non important-
Decreased appetite TRAE (grade 3-4) 3.41 [0.93, 12.49]< 10%1 study (1/-)3.3 %NAnot evaluable non important-
Diabetes TRAE (grade 3-4) 6.05 [0.30, 121.16]< 10%1 study (1/-)12.2 %NAnot evaluable non important-
Diarrhoea TRAE (grade 3-4) 1.44 [0.54, 3.83]< 10%1 study (1/-)23.2 %NAnot evaluable non important-
Fatigue TRAE (grade 3-4) 1.89 [0.75, 4.80]< 10%1 study (1/-)9.0 %NAnot evaluable non important-
Febrile neutropenia TRAE (grade 3-4) 2.66 [1.10, 6.46]< 10%1 study (1/-)1.5 %NAnot evaluable non important-
Guillain-Barré syndrome TRAE (grade 3-4) 1.00 [0.02, 50.55]< 10%1 study (1/-)50.0 %NAnot evaluable non important-
Hepatitis TRAE (grade 3-4) 1.00 [0.06, 16.05]< 10%1 study (1/-)50.0 %NAnot evaluable non important-
Hyperthyroidism TRAE (grade 3-4) 2.00 [0.07, 59.91]< 10%1 study (1/-)34.7 %NAnot evaluable non important-
Hypothyroidism TRAE (grade 3-4) 4.02 [0.18, 89.44]< 10%1 study (1/-)19.3 %NAnot evaluable non important-
Infusion-related reactions TRAE (grade 3-4) 1.00 [0.02, 50.55]< 10%1 study (1/-)50.0 %NAnot evaluable non important-
Leucopenia TRAE (grade 3-4) 1.46 [0.72, 2.93]< 10%1 study (1/-)14.7 %NAnot evaluable non important-
Myalgia TRAE (grade 3-4) 1.00 [0.02, 50.55]< 10%1 study (1/-)50.0 %NAnot evaluable non important-
Myositis TRAE (grade 3-4) 1.00 [0.02, 50.55]< 10%1 study (1/-)50.0 %NAnot evaluable non important-
Nausea TRAE (grade 3-4) 3.55 [0.73, 17.23]< 10%1 study (1/-)5.8 %NAnot evaluable non important-
Nephritis TRAE (grade 3-4) 1.00 [0.02, 50.55]< 10%1 study (1/-)50.0 %NAnot evaluable non important-
Neutropenia TRAE (grade 3-4) 0.93 [0.65, 1.35]< 10%1 study (1/-)64.6 %NAnot evaluable non important-
Pancreatitis TRAE (grade 3-4) 2.00 [0.07, 59.91]< 10%1 study (1/-)34.7 %NAnot evaluable non important-
Peripheral neuropathy TRAE (grade 3-4) 2.01 [0.37, 11.06]< 10%1 study (1/-)21.2 %NAnot evaluable non important-
Peripheral sensory neuropathy TRAE (grade 3-4) 4.04 [0.45, 36.31]< 10%1 study (1/-)10.8 %NAnot evaluable non important-
Pneumonitis TRAE (grade 3-4) 1.68 [0.40, 7.07]< 10%1 study (1/-)24.1 %NAnot evaluable non important-
Rash TRAE (grade 3-4) 2.01 [0.18, 22.23]< 10%1 study (1/-)28.7 %NAnot evaluable non important-
Severe skin reaction TRAE (grade 3-4) 1.00 [0.02, 50.55]< 10%1 study (1/-)50.0 %NAnot evaluable non important-
Thrombocytopenia TRAE (grade 3-4) 1.16 [0.68, 2.00]< 10%1 study (1/-)29.1 %NAnot evaluable non important-
Vomiting TRAE (grade 3-4) 3.02 [0.31, 29.16]< 10%1 study (1/-)17.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons